A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

Timeline

Start

2016-04

Primary completion

2017-02-22

Completion

2018-02-21

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Ixekizumab 80mg Q2W; p <0.001; Odds Ratio (OR) 33.80 (95% CI 12.39 to 92.23); Regression, Logistic NCT02718898 ↗

Drugs

Indications